Chronic myelogenous leukemia progenitors display a genetically unstable personality

Journal of the National Cancer Institute

Volumn 99, Issue 9, 2007, Pages 662-663

  Rodrigues, Margret S ^a,b   Sattler, Martin ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DNA; IMATINIB; INTERFERON; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

CANCER CELL; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; EDITORIAL; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM; NOTE; ONCOGENE; PHYSIOLOGY; STEM CELL;

DRUG RESISTANCE, NEOPLASM; GENES, ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; STEM CELLS;

EID: 34249657931     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djk176     Document Type: Editorial

References (16)

1. Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003;40:4-10.
2. Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA, et al. Survival advantage from imatinib compared to the combination Interferon-α plus cytarabine in chronic phase CML: Historical comparison between two phase III trials. Blood 2006;108:1478-84.
3. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101:4701-7.
4. Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL, et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005;105:2093-8.
5. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction. Blood 2006;107:4532-9.
6. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, et al. Dynamics of chronic myeloid leukaemia. Nature 2005;435:1267-70.
7. Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 2006;57:145-64.
8. Jiang X, Saw KM, Eaves A, Eaves C. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007;99:680-93.
9. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
10. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Laï J-L, Philippe N, Facon T, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002;100: 1014-8.
11. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: Role in inflammatory disease and progression to cancer. Biochem J 1996;313:17-29.
12. Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D, et al. Activation of the P13K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 2005;105: 1717-23.
13. Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T, et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000;275:24273-8.
14. Canitrot Y, Falinski R, Louat T, Laurent G, Cazaux C, Hoffmann JS, et al. p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood 2003;102:2632-7.
15. Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006;108: 319-27.
16. Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004;104:3746-53.